These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22242557)

  • 21. Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
    Marzo I; Naval J
    Biochem Pharmacol; 2013 Sep; 86(6):703-10. PubMed ID: 23886991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
    Malumbres M; Pérez de Castro I
    Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
    Moore AS; Blagg J; Linardopoulos S; Pearson AD
    Leukemia; 2010 Apr; 24(4):671-8. PubMed ID: 20147976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and development of aurora kinase inhibitors as anticancer agents.
    Pollard JR; Mortimore M
    J Med Chem; 2009 May; 52(9):2629-51. PubMed ID: 19320489
    [No Abstract]   [Full Text] [Related]  

  • 26. Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.
    Shang YY; Yu N; Xia L; Yu YY; Ma CM; Jiao YN; Li YF; Wang Y; Dang J; Li W
    Drug Deliv Transl Res; 2020 Feb; 10(1):136-145. PubMed ID: 31625025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
    Carpinelli P; Ceruti R; Giorgini ML; Cappella P; Gianellini L; Croci V; Degrassi A; Texido G; Rocchetti M; Vianello P; Rusconi L; Storici P; Zugnoni P; Arrigoni C; Soncini C; Alli C; Patton V; Marsiglio A; Ballinari D; Pesenti E; Fancelli D; Moll J
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3158-68. PubMed ID: 18089710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
    Schöffski P; Besse B; Gauler T; de Jonge MJ; Scambia G; Santoro A; Davite C; Jannuzzo MG; Petroccione A; Delord JP
    Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora A: target invalidated?
    Cochran AG
    Chem Biol; 2008 Jun; 15(6):525-6. PubMed ID: 18559262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells.
    He SJ; Shu LP; Zhou ZW; Yang T; Duan W; Zhang X; He ZX; Zhou SF
    Cancer Lett; 2016 Nov; 382(2):215-230. PubMed ID: 27612557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aurora-B kinase inhibitors for cancer chemotherapy.
    Yeung SC; Gully C; Lee MH
    Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in Aurora kinase inhibitor patents.
    Coumar MS; Cheung CH; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2009 Mar; 19(3):321-56. PubMed ID: 19441907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aurora A and B kinases--targets of novel anticancer drugs.
    Libertini S; Abagnale A; Passaro C; Botta G; Portella G
    Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Sardon T; Cottin T; Xu J; Giannis A; Vernos I
    Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aurora kinase inhibitors: a new class of targeted drugs in cancer.
    Gautschi O; Mack PC; Davies AM; Lara PN; Gandara DR
    Clin Lung Cancer; 2006 Sep; 8(2):93-8. PubMed ID: 17026809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of danusertib, an Aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells.
    Kirbiyik IA; Ozcimen AA
    J Cancer Res Ther; 2021; 17(6):1419-1424. PubMed ID: 34916372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of Aurora kinase inhibitors in cancer.
    Naruganahalli KS; Lakshmanan M; Dastidar SG; Ray A
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1044-51. PubMed ID: 17209521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.